Cytori Therapeutics (NASDAQ:CYTX) is set to join the broad-market
Russell 3000® Index
when Russell Investments reconstitutes its comprehensive set of U.S. and
global equity indexes on June 27, according to a preliminary list of
additions posted Friday on www.russell.com.
Annual reconstitution of Russell’s U.S.
indexes captures the 4,000 largest U.S. stocks as of the end of May,
ranking them by total market capitalization. Membership in the Russell
3000, which remains in place for one year, means automatic inclusion in
the large-cap Russell 1000®
Index or small-cap Russell 2000®
Index as well as the appropriate growth and value style indexes. Russell
determines membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes. The Russell 3000
also serves as the U.S. component to the Russell Global Index, which
Russell launched last year.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. An industry-leading $4.4 trillion in assets
currently are benchmarked to them. These investment tools originated
from Russell’s multi-manager investment
business in the early 1980s when the company saw the need for a more
objective, market-driven set of benchmarks in order to evaluate outside
investment managers.
About Russell
Russell Investments aims to improve financial security for people by
providing strategic advice, world-class implementation, state-of-the-art
performance benchmarks, and a range of institutional-quality investment
products. With more than $213 billion in assets under management,
Russell serves individual, institutional and advisor clients in more
than 40 countries. Russell provides access to some of the world’s
best money managers. It helps investors put this access to work in
corporate defined benefit and defined contribution plans, and in the
life savings of individual investors. Headquartered in Tacoma, Wash.,
Russell has principal offices in Amsterdam, Auckland, Johannesburg,
London, Melbourne, New York, Paris, San Francisco, Seoul, Singapore,
Sydney, Tokyo and Toronto. For more information on Russell indexes, go
to www.russell.com.
About Cytori
Cytori’s (NASDAQ:CYTX) goal is to be the
global leader in regenerative medicine. The company is dedicated to
providing patients with new options for reconstructive surgery,
developing treatments for cardiovascular disease, and banking patients'
adult stem and regenerative cells. The Celution®
800 System is being introduced in Europe into the reconstructive surgery
market while the Celution®
900 System will be launched in Japan for cryopreserving a patient's own
stem and regenerative cells. Clinical trials are ongoing in
cardiovascular disease and planned for spinal disc degeneration,
gastrointestinal disorders, and other unmet medical needs. www.cytoritx.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating
results and financial position. Such statements are subject to risks and
uncertainties that could cause our actual results and financial position
to differ materially. Some of these risks and uncertainties include our
history of operating losses, the need for further financing, regulatory
uncertainties regarding the collection and results of, clinical data,
dependence on third party performance, and other risks and uncertainties
described under the "Risk Factors" in Cytori’s
Securities and Exchange Commission Filings. We assume no responsibility
to update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made.
Media & Investor Contact:
Cytori Therapeutics
Tom
Baker, 858-875-5258
tbaker@cytoritx.com
